Acquisition and Strategic Realignment - On July 25, 2024, the company acquired Scienture LLC, a specialty pharmaceutical company focused on cardiovascular and central nervous system diseases, which launched its first product for hypertension and is developing a second product for opioid overdose [406]. - The company completed the acquisition of Superlatus on July 31, 2023, with shareholders receiving an aggregate value of $225,000,169 at the time of closing [413]. - The company divested several subsidiaries, including Community Specialty Pharmacy and Alliance Pharma Solutions, as part of a strategic realignment to focus on core operations and enhance long-term value [422]. Financial Performance - Revenues for the year ended December 31, 2025, were $431,609, an increase of $294,966 or approximately 216% compared to $136,643 in 2024, driven by initial sales of ARBLI™ [435]. - Gross profit for 2025 was $331,482, resulting in a gross margin of 76.8%, compared to a gross profit of $6,005 and a gross margin of 4.4% in 2024 [435]. - Total operating expenses for 2025 were $42,922,324, an increase of $28,215,304 from $14,707,020 in 2024, primarily due to non-cash impairment charges of $26,346,050 [436]. - Net loss from continuing operations, net of tax, was $41,512,264 for 2025, compared to a net loss of $15,803,908 in 2024, largely due to the impairment charges [438]. - The net loss for 2025 was $(41,512,264), compared to a net income of $9,065,798 in 2024, indicating a substantial decline in profitability [449]. Cash Flow and Financing - As of December 31, 2025, the company had cash and cash equivalents of $6,662,008 and positive working capital of approximately $5,181,000, an improvement of approximately $6,782,000 from a working capital deficit of $(1,601,416) as of December 31, 2024 [427]. - The company raised approximately $26.3 million in gross equity proceeds through equity line of credit and other transactions during the year ended December 31, 2025 [424]. - The company reported net cash provided by financing activities from continuing operations of $19,733,595 for the year ended December 31, 2025, compared to net cash used of approximately $12,980,000 for the year ended December 31, 2024 [432]. - The company anticipates that its existing cash, combined with growing revenues from product commercialization, will be sufficient to fund operations for at least the next twelve months [428]. Operating Activities and Expenses - Net cash used in operating activities from continuing operations for the year ended December 31, 2025 was $13,382,482, compared to $13,286,163 for the year ended December 31, 2024, with a net loss of $43,507,142 being the primary driver [430]. - Wage and salary expenses remained relatively flat at $2,118,568 in 2025 compared to $2,111,066 in 2024, while professional fees increased by 65% to $2,407,822 [436]. - Research and development expenses decreased to $1,956,270 in 2025 from $2,236,690 in 2024, reflecting shifts in spending across pipeline programs [436]. Tax and Interest - Interest income increased to $302,702 in 2025 from $135,337 in 2024, while interest expense rose significantly to $4,083,206 from $1,335,631 [437]. - The company recognized a tax benefit of $1,994,878 in 2025, reflecting changes in deferred tax liabilities due to impairment charges [437]. EBITDA and Impairment Charges - For the year ended December 31, 2025, adjusted EBITDA was $(5,384,274), a significant decrease from $17,820,898 in 2024, reflecting the transition to a focused specialty pharmaceutical company [449]. - The company recognized non-cash impairment charges of $26,346,050 in 2025, impacting the adjusted EBITDA [449]. Other Financial Information - There was no income from discontinued operations in 2025, compared to $27,310,278 in 2024, primarily from the sale of MMS assets [438]. - Depreciation and amortization expenses increased to $491,781 in 2025 from $53,361 in 2024, highlighting increased operational costs [449]. - Stock-based compensation (non-cash) increased to $6,378,981 in 2025 from $4,623,878 in 2024, indicating a rise in employee compensation costs [449]. - The company did not have any off-balance sheet arrangements during the periods presented [450]. - The company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures [452].

Financial Performance - Vor Bio reported a net loss of $696.0 million for the year ended December 31, 2025, compared to a net loss of $116.9 million for the year ended December 31, 2024, representing an increase in losses of $579.1 million[438][454]. - Total operating expenses for 2025 were $371.6 million, a significant increase of $250.5 million from $121.2 million in 2024[454]. - Vor Bio's accumulated deficit reached $1,153.0 million as of December 31, 2025[438]. - Net cash used in operating activities was $142.7 million for the year ended December 31, 2025, reflecting a net loss of $696.0 million[475]. - Other income (expense), net decreased by $328.6 million for the year ended December 31, 2025, primarily due to a $334.4 million loss on the change in fair value of warrant liabilities[458]. Research and Development - Research and development expenses surged to $321.5 million in 2025, up from $93.3 million in 2024, primarily due to a $222.6 million expense for the telitacicept license acquisition[456]. - Vor Bio initiated a global Phase 3 clinical trial for telitacicept in Sjögren's disease, with first patient dosing in March 2026, aiming to recruit approximately 250 adults[436]. - Vor Bio's Phase 3 clinical trial for generalized myasthenia gravis (gMG) is currently recruiting patients globally, with topline data expected in the first half of 2027[434]. - The company expects to incur substantial additional costs associated with clinical trials and regulatory approvals, which may delay revenue generation[469][470]. Funding and Cash Position - As of December 31, 2025, Vor Bio had cash, cash equivalents, and marketable securities totaling $455.2 million, expected to fund operations into early 2029[439]. - Net cash provided by financing activities was $503.8 million for the year ended December 31, 2025, including $175.0 million from the June 2025 Private Placement and $107.7 million from the November 2025 Offering[479]. - The company raised approximately $1,019.1 million from equity securities sales as of December 31, 2025, to fund operations[459]. - The December 2025 Private Placement resulted in net proceeds of $149.9 million after issuing 13,876,032 shares at a price of $10.81 per share[465]. - The company sold 1,910,861 shares under the Stifel ATM Facility in 2025, generating net proceeds of $70.1 million at a weighted average price of $37.06 per share[461]. - The company anticipates needing substantial additional funding to support ongoing operations and growth strategies, with potential impacts from global economic conditions[472]. Corporate Structure and Compliance - The company has elected to use the extended transition period for complying with new or revised accounting standards, delaying adoption until they apply to private companies[489]. - As an emerging growth company, the company benefits from reduced disclosure requirements until the end of the fiscal year following the fifth anniversary of its IPO or until it no longer qualifies[490]. - The company may present only two years of audited consolidated financial statements, with reduced disclosure in the Management's Discussion and Analysis section[491]. - The company is classified as a smaller reporting company, allowing it to continue relying on exemptions from certain disclosure requirements after ceasing to be an emerging growth company[493]. - The company is not required to provide quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company[495]. Restructuring and Workforce - The company has incurred restructuring costs of $29.7 million related to its Restructuring Plan, which included a workforce reduction of 154 employees, approximately 99% of its then-current employee base[440][441].

Financial Performance - The net loss attributable to common stockholders for Q4 2025 was $79.7 million, compared to $64.9 million in the prior-year period[11]. - For the full year 2025, the net loss attributable to common stockholders was $333.6 million, up from $243.8 million in 2024[11]. - Total operating expenses for 2025 were $338.9 million, compared to $260.3 million in 2024[18]. Funding and Cash Position - Eikon raised $381 million in gross proceeds from an upsized IPO in February 2026, strengthening its balance sheet[4]. - As of December 31, 2025, Eikon had cash, cash equivalents, and marketable securities of $336 million, expected to fund operations into the second half of 2027[7]. - Eikon's total assets as of December 31, 2025, were $594.7 million, an increase from $491.2 million in 2024[20]. Research and Development - R&D expenses for Q4 2025 were $65.2 million, a 21% increase from $53.9 million in Q4 2024, primarily due to accelerated clinical trial activity[8]. - For the full year 2025, R&D expenses totaled $250.3 million, up 22% from $204.5 million in 2024, driven by expanded clinical trials and increased facility costs[8]. - Eikon completed enrollment in the TeLuRide-005 Phase 2 trial for EIK1001 in first-line treatment of stage 4 non-small cell lung cancer, with data expected in 2H 2026[4]. General and Administrative Expenses - G&A expenses for Q4 2025 were $17.9 million, a 29% increase from $13.9 million in Q4 2024, mainly due to higher compensation costs[10].

Securities Offering - Bicara Therapeutics Inc. plans to issue 7,175,000 shares of common stock and pre-funded warrants to purchase up to 2,200,000 shares at an exercise price of $0.0001[4] - The company may issue an additional 1,406,250 shares of common stock if the underwriters exercise their option to purchase additional shares[4] - The public offering price for the shares is set at $16.00 per share, with a concession of up to $0.5760 per share for certain dealers[62] - The Pre-Funded Warrants are offered at an initial price of $15.9999 per warrant, also with a concession of up to $0.5760 per warrant for selected dealers[62] - The Company agrees to sell Firm Shares at a price of $15.0400 per share to underwriters[59] - The underwriters have the right to purchase up to 1,406,250 Additional Shares at the same purchase price[60] - Payment for the Firm Securities is scheduled for February 26, 2026, with a deadline for any Additional Shares payment by April 9, 2026[63] - The Closing Date for the offering is February 26, 2026[124] - The number of Firm Shares is 7,175,000[124] - The number of Pre-Funded Warrants is 2,200,000[124] - The number of Additional Shares is 1,406,250[124] Compliance and Legal Matters - The registration statement for the securities has been filed with the Securities and Exchange Commission and is effective[7] - The company has not experienced any material adverse changes in its financial condition or operations since the last prospectus[17] - Bicara Therapeutics Inc. is in compliance with all applicable laws and regulations, including those related to environmental protection[21] - The company has received all necessary permits and licenses required under environmental laws to conduct its business[21] - There are no pending legal proceedings that would materially affect the company or its subsidiaries[18] - The Company is not required to register as an "investment company" under the Investment Company Act of 1940 after the offering[20] - The Company has not received any adverse communications from regulatory authorities regarding compliance with regulatory laws[52] Financial Condition - The Company has not incurred any material liability or obligation, nor entered into any material transaction since the last reporting date[32] - There has been no material change in the capital stock, short-term debt, or long-term debt of the Company and its subsidiaries[32] - Financial statements have been prepared in accordance with U.S. GAAP and present a fair view of the Company's consolidated financial position[44] - KPMG LLP has certified the Company's financial statements, confirming their independence and compliance with applicable regulations[45] - The Company has no material weaknesses in internal controls over financial reporting since the last audited fiscal year[46] - The Company has filed all required tax returns and paid all necessary taxes, with no material adverse tax deficiencies reported[49] Operational Integrity - The Company and its subsidiaries have good and marketable title to all real and personal property material to their business, free of liens and encumbrances[33] - The Company owns or has valid licenses for all necessary Intellectual Property Rights for its business operations[34] - The Company has complied with all applicable Data Security Obligations and has not received any notifications indicating non-compliance[39] - The Company has taken reasonable measures to protect its information technology systems and data from breaches[40] - There are no material labor disputes with the employees of the Company or its subsidiaries[41] - The Company is insured against losses and risks in amounts deemed prudent and customary for its business[42] - The Company has maintained compliance with all necessary permits and regulatory requirements, ensuring no material adverse effects on operations[43] Underwriter Agreements - The obligations of the Underwriters are contingent upon no material adverse changes in the Company's financial condition or operations prior to the Closing Date[68] - The Chief Financial Officer is required to deliver a certificate to the Underwriters confirming compliance with all agreements on the Closing Date[77] - KPMG LLP will provide a comfort letter regarding the financial statements included in the Registration Statement on the Closing Date[75] - Lock-up agreements with officers and directors regarding restrictions on sales of shares must be in effect on the Closing Date[76] - The Company is obligated to furnish signed copies of the Registration Statement and related documents upon request from the Underwriters[81] - The Company must prepare and file any necessary amendments or supplements to the Time of Sale Prospectus to ensure compliance with applicable law[85] - The Company will not be required to qualify as a foreign corporation or dealer in securities in jurisdictions where it is not otherwise required[87] - The Company will make available an earnings statement covering a period of at least twelve months after the first fiscal quarter following the date of the Agreement[88] - The Company will pay all expenses related to the registration and delivery of the Securities, including legal and accounting fees, with specific caps on certain costs such as $10,000 for Blue Sky memorandum[89] - The Company will notify the Representatives if it ceases to be an Emerging Growth Company prior to the completion of the distribution of the Securities[90] - The Company will not publicly disclose intentions to offer or sell any shares of Common Stock during the 60-day Restricted Period following the date of the Prospectus[93] - The Company may issue up to 3% of its total outstanding share capital in connection with mergers or acquisitions during the Restricted Period[94] Indemnification and Liability - The Company agrees to indemnify Underwriters against losses arising from untrue statements or omissions in the Registration Statement or related documents[96] - Each Underwriter agrees to indemnify the Company for losses related to information they provided for the Registration Statement[97] - The indemnifying party will be liable for legal expenses incurred by the indemnified party in connection with any proceeding[98] - The Company will contribute to losses if indemnification is unavailable or insufficient, reflecting the relative fault of each party[99] - The Company and Underwriters agree on the allocation of benefits and liabilities based on the net proceeds from the offering of the Securities, reflecting the respective contributions of both parties[100] - The indemnity provisions remain effective regardless of any termination of the Agreement or investigations conducted by the Underwriters or the Company[102] Agreement Terms - The Underwriters may terminate the Agreement if trading is suspended or materially limited on relevant exchanges, or if there is a material disruption in securities settlement services[103] - If any Underwriter fails to purchase Securities, the other Underwriters are obligated to purchase the shortfall, provided it does not exceed one-tenth of the total Securities[104] - The Company will reimburse Underwriters for out-of-pocket expenses incurred if the Agreement is terminated due to the Company's failure to comply with its terms[106] - The Agreement represents the entire understanding between the Company and Underwriters regarding the offering of the Securities[107] - The Company acknowledges that the Underwriters have acted at arm's length and owe no fiduciary duties beyond those specified in the Agreement[108] - The Agreement is governed by the internal laws of the State of New York, ensuring legal clarity and compliance[113] - All communications regarding the Agreement must be in writing and effective only upon receipt, with specified addresses for both parties[114][115] - The Agreement allows for electronic signatures, which hold the same validity as traditional signatures[112]

Financial Results Announcement - Sensei Biotherapeutics, Inc. announced its financial results for the full year ended December 31, 2025, on March 30, 2026[4]. - The press release detailing the financial results is attached as Exhibit 99.1[4]. - The report does not include specific financial metrics or performance indicators, as the detailed financial results are in the attached press release[4]. Regulatory Compliance - The company is classified as an emerging growth company under the Securities Act of 1933[3]. - The report was filed under the Securities Exchange Act of 1934, indicating compliance with regulatory requirements[5]. - The filing does not incorporate any information by reference into other filings under the Exchange Act or the Securities Act[5]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[3]. Company Information - The company's principal executive offices are located in Rockville, MD[1]. - The common stock of Sensei Biotherapeutics is traded on The Nasdaq Stock Market under the symbol SNSE[2]. - The report was signed by Christopher W. Gerry, President and General Counsel, on March 30, 2026[10].

Financial Performance - The company reported a net loss of $28 million for 2025, an increase of $17 million from the previous year, attributed to higher R&D, G&A, and interest expenses[8] - Total revenue for 2024 was $248,357, with no revenue reported for 2025[20] - Operating expenses increased significantly to $25,196,475 in 2025 from $10,601,899 in 2024, representing a 137.5% increase[20] - The net loss for 2025 was $28,016,641, compared to a net loss of $11,485,410 in 2024, indicating a 144.5% increase in losses year-over-year[20] - Loss per common share for 2025 was $0.39, up from $0.19 in 2024, reflecting a 105.3% increase in loss per share[20] - Comprehensive loss for 2025 was $27,147,924, compared to $11,089,885 in 2024, indicating a 144.5% increase[20] Cash and Investments - As of December 31, 2025, Terrestrial Energy held approximately $298 million in cash and short-term investments, a significant increase from $3.29 million in 2024[8] - Cash flows from investing activities totaled $200,638,289 in 2025, primarily due to the purchase of short-term investments amounting to $199,496,832[24] - Cash and cash equivalents at the end of 2025 were $97,164,391, a significant increase from $3,021,795 at the beginning of the year[24] - The company raised $311,394,447 from financing activities in 2025, a substantial increase compared to $7,254,268 in 2024[24] Expenses Breakdown - Research and development costs rose to $9,767,996 in 2025, compared to $5,176,932 in 2024, marking an increase of 88.5%[20] - General and administrative expenses surged to $14,266,775 in 2025 from $4,168,576 in 2024, a 242.5% increase[20] - Interest expense for 2025 was $3,900,997, compared to $1,223,929 in 2024, which is a 219.5% increase[20] - Stock-based compensation increased to $3,103,702 in 2025 from $670,243 in 2024, indicating a focus on incentivizing employees[24] Strategic Initiatives - Terrestrial Energy completed a business combination, raising approximately $292 million in gross proceeds, and began trading on Nasdaq under the ticker symbol IMSR[1] - The U.S. Nuclear Regulatory Commission accepted the IMSR Principal Design Criteria, marking a key step in licensing readiness for IMSR plant construction[3] - Terrestrial Energy received two "OTA" awards from the U.S. Department of Energy, supporting the TETRA project and the Fuel Line Assembly project, which are crucial for IMSR plant licensing and operation[3] - The company expanded its commercial reach through collaboration with Ameresco, enhancing its ability to execute IMSR plant projects across the U.S.[3] - Texas A&M University selected Terrestrial Energy to site a full-sized commercial IMSR Plant at its RELLIS campus, positioning it among the first commercial Generation IV reactor deployments[3] - The company is in the concluding phase of its reactor graphite irradiation and supplier selection program, essential for IMSR plant licensing and operation[3] Shareholder Information - As of December 31, 2025, Terrestrial Energy had 105.8 million shares issued and outstanding, including approximately 81.8 million common shares[8] - The weighted-average shares of common shares outstanding increased to 71,646,985 in 2025 from 60,414,175 in 2024, a growth of 18.6%[20] - The company recognized $29,787,900 from the conversion of convertible notes to common shares, indicating a strategic move to strengthen equity[24] - Proceeds from the issuance of Series A-1 preferred shares amounted to $25,797,201, contributing to the financing activities[24] - The company incurred $22,305,729 in transaction costs related to merger and recapitalization activities, reflecting ongoing strategic initiatives[24] Currency and Exchange Rate Impact - The company reported a foreign currency translation adjustment loss of $260,731 in 2025, contrasting with a gain of $395,525 in 2024[20] - The effect of exchange rate changes on cash and cash equivalents resulted in a decrease of $140,650, highlighting potential currency risk[24] Future Outlook - The company plans to provide updates on expected 2026 milestones, including commercial, regulatory, and development progress during the earnings call[5]

Financial Performance - The company reported a net loss of $28 million for 2025, an increase of $17 million from the previous year, attributed to higher R&D, G&A, and interest expenses [8]. - Total revenue for 2024 was $248,357, with no revenue reported for 2025 [20]. - Operating expenses increased significantly to $25,196,475 in 2025 from $10,601,899 in 2024, representing a 137.5% increase [20]. - The net loss for 2025 was $28,016,641, compared to a net loss of $11,485,410 in 2024, indicating a 144.5% increase in losses year-over-year [20]. - Loss per common share for 2025 was $0.39, up from $0.19 in 2024, reflecting a 105.3% increase in loss per share [20]. - Comprehensive loss for 2025 was $27,147,924, compared to $11,089,885 in 2024, representing a 144.5% increase [20]. - The company reported a foreign exchange loss of $57,214 in 2025, contrasting with a gain of $617,357 in 2024 [20]. Cash and Investment Activities - As of December 31, 2025, Terrestrial Energy held approximately $298 million in cash and short-term investments, a significant increase from $3.29 million in 2024 [8]. - Net cash used in operating activities for 2025 was $16,472,912, up from $8,202,934 in 2024, reflecting higher operational expenditures [24]. - Total cash and cash equivalents at the end of 2025 reached $97,164,391, a substantial increase from $3,021,795 at the beginning of the year [24]. - Net cash used in investing activities was $200,638,289 in 2025, compared to $662,270 in 2024, highlighting increased investment activities [24]. - Net cash provided by financing activities amounted to $311,394,447 in 2025, a significant rise from $7,254,268 in 2024, driven by various financing efforts [24]. - Proceeds from the issuance of convertible notes totaled $9,335,000 in 2025, compared to $6,563,000 in 2024, indicating increased capital raising efforts [24]. - The company made purchases of intangible assets totaling $86,150 in 2025, compared to $54,404 in 2024, suggesting ongoing investment in intellectual property [24]. Research and Development - Research and development costs rose to $9,767,996 in 2025, compared to $5,176,932 in 2024, marking an increase of 88.5% [20]. - The company is in the concluding phase of its reactor graphite irradiation and supplier selection program, essential for IMSR plant licensing and operation [3]. Regulatory and Licensing Developments - The U.S. Nuclear Regulatory Commission accepted the IMSR Principal Design Criteria, marking a key step in licensing readiness for IMSR plant construction [3]. - Terrestrial Energy received two "OTA" awards from the U.S. Department of Energy, supporting the TETRA project and the Fuel Line Assembly project, which are crucial for IMSR plant licensing and operation [3]. - Texas A&M University selected Terrestrial Energy to site a full-sized commercial IMSR Plant at its RELLIS campus, positioning it among the first commercial Generation IV reactor deployments [3]. Shareholder Information - As of December 31, 2025, Terrestrial Energy had 105.8 million shares issued and outstanding, including approximately 81.8 million common shares [8]. - The weighted-average shares of common shares outstanding increased to 71,646,985 in 2025 from 60,414,175 in 2024, an increase of 18.5% [20]. Future Outlook - The company plans to provide updates on expected 2026 milestones, including commercial, regulatory, and development progress during the earnings call [5].

Financial Performance - Net loss attributable to common stockholders for the year ended December 31, 2025, was $26.6 million, or $1.67 per share, a decrease from a net loss of $37.8 million, or $5.65 per share, in 2024[7] - Total operating expenses for the year ended December 31, 2025, were $29.5 million, down from $32.1 million in 2024[17] - The change in fair value of the warrant liability resulted in other income of $2.0 million for the year ended December 31, 2025, compared to an expense of $5.8 million in 2024[16] Cash and Assets - As of March 30, 2026, the company reported unaudited cash, cash equivalents, and marketable securities totaling $54.9 million, providing a runway into 2027[8] - Total assets increased to $49.1 million as of December 31, 2025, from $31.7 million in 2024[15] - Stockholders' equity rose to $30.2 million as of December 31, 2025, compared to $7.4 million in 2024[15] Expenses - Research and Development (R&D) expenses decreased to $9.1 million for the year ended December 31, 2025, from $20.0 million in 2024, primarily due to reduced drug development and clinical trial costs[5] - General and Administrative (G&A) expenses increased to $20.4 million for the year ended December 31, 2025, compared to $12.1 million in 2024, driven by higher consulting and commercial launch preparation costs[6] - Total operating expenses for the year ended December 31, 2025, were $29.5 million, down from $32.1 million in 2024[17] Regulatory and Commercial Activities - The FDA accepted the resubmission of the New Drug Application (NDA) for oxylanthanum carbonate (OLC), with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026[10] - The company is preparing for a potential commercial launch of OLC in the third quarter of 2026, with ongoing commercial readiness activities[9]

Corporate Structure and Financial Transactions - ECARX Holdings is a Cayman Islands holding company, and investors are acquiring interest in this holding company rather than in any operating company[26]. - In 2023, ECARX Technology Limited repaid US$119.3 million to ECARX Holdings, while ECARX Holdings made advances totaling US$115.0 million to ECARX Group Limited and US$2.7 million to ECARX Technology Limited[41]. - In 2024, ECARX Holdings made advances of US$12.5 million to ECARX Group Limited and US$1.0 million to ECARX Technology Limited[41]. - In 2025, ECARX Holdings made advances totaling US$42.0 million to ECARX Group Limited and US$62.4 million to ECARX Technology Limited[41]. - The restructuring in 2022 terminated the VIE corporate structure, which had been subject to increased regulatory scrutiny, and currently, there are no VIEs in China[28]. - As of the date of the annual report, none of the mainland China subsidiaries has been subject to penalties for failing to obtain necessary business licenses or permits[32]. - The company has not declared or paid dividends and does not intend to do so in the near future[43]. - Restrictions exist on inter-company fund transfers and foreign exchange control affecting dividend payments from mainland China subsidiaries[44]. - Current regulations allow mainland China subsidiaries to pay dividends only from accumulated after-tax profits, which may limit cash flow to the parent company[196]. - As of December 31, 2025, many mainland China subsidiaries reported accumulated losses, affecting their ability to pay dividends[197]. - Limitations on dividend payments from mainland China subsidiaries could adversely impact the company's ability to grow and invest[198]. - The withholding tax rate on dividends from mainland China subsidiaries to foreign enterprises is currently 10%, potentially reduced to 5% if certain conditions are met[221]. - As of December 31, 2025, most subsidiaries in mainland China reported accumulated losses, resulting in no retained earnings available for offshore distribution[221]. - The company intends to reinvest any earnings generated from mainland China subsidiaries for business operations and expansion in China[221]. Regulatory Environment and Compliance - The PCAOB has not issued any new determination that it is unable to inspect or investigate registered public accounting firms in any jurisdiction, which is crucial for compliance with the Holding Foreign Companies Accountable Act[30]. - The PRC government has intensified control over overseas capital raising by China-based issuers, which may affect future operations[33]. - As of the date of the report, ECARX Holdings does not expect to be identified as a Commission-Identified Issuer under the HFCAA after filing the annual report for the fiscal year ended December 31, 2025[31]. - The company is subject to evolving cybersecurity and data protection laws, with potential breaches leading to reputational damage and legal liabilities[108]. - The company has implemented strict information security policies, but risks remain due to the evolving nature of cyber threats[110]. - The company may face increased compliance costs and obligations due to new regulations on data security and privacy in China[112]. - The company is subject to complex regulatory standards in the U.S. and Europe, including the GDPR, which imposes additional obligations regarding personal data handling[117]. - The company has incurred significant expenses to comply with privacy and data protection standards, which may increase due to changes in laws and regulations[118]. - The PRC government may impose restrictions on foreign investments and overseas offerings, affecting the company's ability to operate and raise capital[171]. - The company must comply with confidentiality and archives management requirements during overseas offerings, which could complicate operations[176]. - Any changes in regulatory requirements could significantly impact the company's ability to conduct business and the value of its securities[181]. - The PCAOB was historically unable to inspect auditors in mainland China, impacting investor confidence in audit quality[182]. - As of December 15, 2022, the PCAOB removed mainland China and Hong Kong from the list of jurisdictions it cannot fully inspect[184]. - If the PCAOB loses access to inspect auditors in mainland China again, the company's securities may be prohibited from trading in the U.S. under the HFCAA[183]. - The SEC may prohibit trading of the company's securities if audit reports are issued by firms not inspected by the PCAOB for two consecutive years[183]. - Regulatory scrutiny from the SEC may increase compliance costs and complicate future securities offerings for companies with substantial operations in China[187]. - M&A activities in mainland China are subject to complex regulations, potentially hindering growth through acquisitions[188]. - The 2019 PRC Foreign Investment Law introduces uncertainties regarding foreign investment regulations and compliance requirements[190]. - The evolving legal system in China presents uncertainties that could limit legal protections and impact the company's operations and reputation[168]. - New regulations regarding overseas offerings and listings by mainland China-based companies may impose additional compliance requirements[174]. - The company may face significant uncertainties regarding the interpretation and implementation of the Overseas Listing Filing Rules and data security regulations[178]. - Failure to obtain necessary approvals or complete required filings could result in regulatory sanctions, including fines and operational restrictions[180]. - The company has not been involved in any cybersecurity reviews or received inquiries from PRC authorities as of the report date[176]. Financial Performance and Risks - The company has experienced negative net cash flows from operations in the past and has not been profitable, raising concerns about its ability to continue as a going concern[51]. - The company incurred net losses of US$143.9 million, US$137.8 million, and US$68.9 million in 2023, 2024, and 2025, respectively, and has not been profitable since inception[76]. - Negative cash flows from operating activities were US$172.4 million, US$60.0 million, and US$94.4 million in 2023, 2024, and 2025, respectively[76]. - The company has a net current liability of US$339.8 million as of December 31, 2025[76]. - The automotive intelligence industry is highly competitive, and the company faces significant challenges in a fast-developing market[51]. - The demand for the company's products is closely tied to automobile sales and production, which can be cyclical and influenced by various economic factors[62]. - Supply chain disruptions, particularly in semiconductor manufacturing, could materially affect production and profitability[67]. - The company is investing significantly in research and development to advance its automotive intelligence technologies, but market acceptance remains uncertain[60]. - The automotive intelligence market is expected to become more competitive, with increased demand for automotive intelligence technologies and ongoing industry consolidation[73]. - The company faces risks associated with international operations, including increased regulatory risks and local competition[83]. - The company relies on a concentrated customer base, particularly Geely Holding, which poses risks if key customer relationships are disrupted[79]. - The company may need to seek additional equity or debt financing to support its operations, which could dilute shareholders or impose operational restrictions[92]. - The company may face challenges in obtaining necessary financing due to market conditions, which could lead to reduced spending or changes in corporate structure[93]. - Future capital needs may require the issuance of additional equity or debt securities, potentially diluting shareholder interests and increasing debt service obligations[94]. - The company has completed several acquisitions, including controlling interests in JICA Intelligent and Suzhou Photon-Matrix, and plans to continue pursuing strategic investments to enhance its product offerings[96]. - The company is exposed to risks from warranty claims and product liabilities, which could adversely affect profitability and financial position[97]. - Expansion or conversion of production facilities may encounter delays and cost overruns, impacting production capacity and financial results[102]. - Compliance with environmental laws and regulations may impose substantial costs and cause delays in building production facilities[105]. - The company relies heavily on consumer spending in China, with revenues significantly impacted by economic conditions domestically and globally[131]. - Economic slowdown in China could materially and adversely affect the company's business and financial condition[131]. - Heightened geopolitical tensions, particularly between the U.S. and China, may negatively impact trade, investments, and the company's operations[135]. - The U.S. has imposed higher tariffs on certain products imported from China, which could adversely affect the company's sales and financial results[136]. - Ongoing geopolitical conflicts, such as those in the Red Sea and Ukraine, could disrupt global economic activities and supply chains, adversely affecting the company's operations[144]. - The company is vulnerable to natural disasters and other calamities, which could disrupt operations and adversely affect financial results[146]. - The company may incur substantial costs defending against intellectual property infringement claims, which could materially affect business operations[151]. - The company relies on information technology systems for daily operations, and disruptions could lead to significant costs and impact financial condition[160]. - The company has not experienced any material interruptions due to cyber-attacks or security breaches to date, but risks remain[162]. - The company may face claims related to open-source software usage, which could result in significant legal costs and impact proprietary software distribution[163]. Human Resources and Labor Costs - Labor costs in China are expected to increase, impacting profitability unless passed on to service payers[201]. - Stricter regulatory requirements for labor contracts and employee benefits may adversely affect business operations[202]. - The company relies heavily on its executive officers and key employees, and losing their services could severely disrupt operations and financial performance[124]. Intellectual Property and Technology - The company has 779 registered patents and 797 pending patent applications globally as of December 31, 2025[156]. - The company's ability to protect its intellectual property is critical, and unauthorized use by third parties could harm competitive position and revenues[154]. - The company's management concluded that internal control over financial reporting was effective as of December 31, 2025[149]. Brand and Reputation - The company's brand and reputation are vulnerable to negative publicity, which could harm its business and financial condition[128]. - Non-compliance with anti-corruption and anti-bribery laws could lead to severe penalties and adversely affect the company's reputation and financial condition[119]. - The company has limited insurance coverage, exposing it to significant costs and potential business disruptions[123].

Funding and Government Support - The U.S. government is expected to provide $1.6 billion in funding under the CHIPS Act to accelerate the establishment of a secure domestic supply chain for rare earths[34] - The implementation of DFARS 225.7018 will prohibit the Department of War from acquiring certain magnets produced in China, highlighting the need for compliant domestic supply chains[57] - The company is subject to agreements with government entities that provide incentives, which if not complied with, could negatively impact business operations[182] Project Development and Production Plans - The Accelerated Mining Plan anticipates the start of commercial production at Round Top in late 2028, leveraging one of North America's richest heavy rare earth deposits[34] - The planned production timeline for the Round Top Mountain project has been accelerated, targeting commercial production by late 2028, two years earlier than previously planned[73] - The Round Top Project, which includes land and water rights, is a joint venture where the company holds an 81.3% interest, aiming to streamline operations and enhance economic benefits[48] - The proposed TMRC Merger Agreement aims to secure 100% economic interest in the Round Top Project, enhancing operational efficiency[50] - The Colorado research and development facility is expected to become one of the largest solvent extraction demo facilities in the U.S., with over 500 planned mixer/settlers[76] Acquisitions and Strategic Relationships - The acquisition of Less Common Metals is expected to enhance industry relationships and improve control over the value chain, with plans to expand metal making capabilities to 3,750 metric tons per year in France[34] - Less Common Metals has established relationships with European defense and industrial customers, positioning itself to meet DFARS-compliant material requirements ahead of the January 2027 prohibition on Chinese-origin REE magnets in U.S. weapons systems[87] - The success of the LCM Acquisition relies on retaining existing customers and suppliers, as well as building new relationships[202] Production Capacity and Technology - The Stillwater Facility has successfully commissioned Phase 1a of sintered NdFeB permanent magnet block production, with customer orders expected to begin in Q2 2026[40] - The Stillwater Facility's Phase 1a is expected to produce approximately 600 MTPA of sintered NdFeB permanent magnet blocks at full capacity, with Phase 1b anticipated to match this output[89] - The company is developing a fully integrated mine-to-magnet platform essential for various industrial sectors, including aerospace and defense[50] - Advanced grain-boundary-diffusion technology enhances magnetic performance while reducing the need for both LREEs and HREEs, supporting sustainable solutions[92] Market Dynamics and Competition - Heavy rare earth elements are critical for U.S. defense and advanced technology platforms, with China controlling approximately 99% of global processing[54] - The company faces significant competition from China, which controls a substantial majority of the global rare earth magnet production and benefits from government support[97] - Domestically, competition includes MP Materials, Noveon Magnetics, and VACUUMSCHMELZE, with emerging competitors like KSM Metals also entering the market[98] - The market for neo magnets is influenced by global supply and demand dynamics, with China dominating production and regulatory factors affecting pricing[167] Financial Performance and Risks - The company incurred a net loss of $298.5 million for the year ended December 31, 2025, with an accumulated deficit of $387.4 million as of the same date[157] - The company's revenues for 2025 were solely derived from the Less Common Metals business, with no revenue generated from neo magnet manufacturing or mineral production[157] - The company anticipates needing additional capital to fund ongoing operations and complete the Stillwater Facility, with potential reliance on equity or debt financing[172] - The company does not currently have any contractually committed customers for neo magnets, which could negatively impact revenue generation[160] Environmental and Regulatory Compliance - Environmental regulations significantly impact operations, with ongoing expenditures expected for compliance and sustainability initiatives[107] - The company is subject to various environmental, health, and safety regulations in the U.K. and EU, which may impose significant compliance costs and operational constraints[122][123] - The mining industry is particularly exposed to stringent regulations regarding greenhouse gas emissions, which may materially impact the company's financial condition and operational prospects[230] - Compliance with anti-corruption and anti-bribery laws is critical, as failure to do so may result in significant sanctions, including criminal fines and civil penalties[227] Research and Development - The R&D Program focuses on developing various NdFeB grades, including high-temperature grades critical for defense applications, which can maintain performance above 150°C[91] - Research and development programs are critical for establishing commercially viable extraction and manufacturing operations, but success is not guaranteed[150] Operational Challenges - The company faces risks from potential economic contractions that could lead to lower prices for neo magnets, impacting revenues and development funds[166] - Disruptions in power supply at projects could delay operations and increase costs, adversely affecting revenue and customer relationships[177] - Diminished access to water could adversely affect operations, especially with increased water requirements post-Round Top Project completion[181] - The company must implement adequate health and safety systems to mitigate risks associated with workplace hazards, which could have a material effect on its reputation and financial condition[224]